Details for Patent: RE43431

Which drugs does patent RE43431 protect, and when does it expire?

Patent RE43431 protects GILOTRIF and is included in one NDA.

Protection for GILOTRIF has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-five patent family members in thirty-eight countries.

Summary for Patent: RE43431

Title:	Quinazoline derivatives and pharmaceutical compositions containing them
Abstract:	A compound of general formula I ##STR00001## wherein: R.sub.a is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; R.sub.b is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and R.sub.c is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.
Inventor(s):	Himmelsbach; Frank (Mittelbiberach, DE), Langkopf; Elke (Biberach an der Riss, DE), Blech; Stefan (Warthausen, DE), Jung; Birgit (Laupheim, DE), Baum; Anke (Vienna, AT), Solca; Flavio (Vienna, AT)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:	12/542,929
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE43431
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent RE43431

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-001	Jul 12, 2013		RX	Yes	No					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-002	Jul 12, 2013		RX	Yes	No					Y
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-003	Jul 12, 2013		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: RE43431

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	100 63 435	Dec 20, 2000

International Family Members for US Patent RE43431

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1345910		452	Finland
European Patent Office	1345910		C300643	Netherlands
European Patent Office	1345910		CA 2014 00006	Denmark
European Patent Office	1345910		PA2014005	Lithuania
European Patent Office	1345910		92370	Luxembourg
European Patent Office	1345910		PA2014005,C1345910	Lithuania
European Patent Office	1345910		14C0009	France